|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:Horizon_Therapeutics
gptkb:Immunex
gptkb:Onyx_Pharmaceuticals
gptkb:deCODE_genetics
|
|
gptkbp:awarded
|
gptkb:National_Medal_of_Technology_and_Innovation_(2010)
|
|
gptkbp:CEO
|
gptkb:Robert_A._Bradway
|
|
gptkbp:competitor
|
gptkb:Biogen
gptkb:AbbVie
gptkb:Genentech
gptkb:Gilead_Sciences
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:dividendPaying
|
yes
|
|
gptkbp:ESRB_rating
|
gptkb:A_(MSCI,_2023)
|
|
gptkbp:foundedYear
|
1980
|
|
gptkbp:founder
|
gptkb:George_Rathmann
|
|
gptkbp:headquartersLocation
|
gptkb:Thousand_Oaks,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Amgen
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:NASDAQ-100
gptkb:S&P_500
|
|
gptkbp:marketCap
|
over $100 billion (2023)
|
|
gptkbp:memberOf
|
gptkb:Biotechnology_Innovation_Organization
|
|
gptkbp:netIncome
|
$6.7 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Aimovig
gptkb:Aranesp
gptkb:Enbrel
gptkb:Epogen
gptkb:Neulasta
gptkb:Prolia
gptkb:Repatha
gptkb:Xgeva
|
|
gptkbp:numberOfEmployees
|
~25,200
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:patent
|
over 1,000
|
|
gptkbp:researchInterest
|
gptkb:cardiovascular_disease
neuroscience
oncology
nephrology
inflammation
bone health
|
|
gptkbp:revenue
|
$26.3 billion (2023)
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:AMGN
|
|
gptkbp:subsidiary
|
gptkb:Immunex
gptkb:Onyx_Pharmaceuticals
gptkb:deCODE_genetics
|
|
gptkbp:website
|
https://www.amgen.com/
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ-100
gptkb:Ronald_D._Sugar
gptkb:South_San_Francisco
gptkb:Phil_Mickelson
gptkb:Rebecca_Henderson
gptkb:Syapse_Inc.
gptkb:Thousand_Oaks
gptkb:Array_BioPharma
gptkb:Munger,_Tolles_&_Olson
gptkb:Thousand_Oaks,_California
gptkb:NOVN
|
|
gptkbp:bfsLayer
|
5
|